CN102994500B - 治疗眼部疾病的方法 - Google Patents

治疗眼部疾病的方法 Download PDF

Info

Publication number
CN102994500B
CN102994500B CN201210278029.7A CN201210278029A CN102994500B CN 102994500 B CN102994500 B CN 102994500B CN 201210278029 A CN201210278029 A CN 201210278029A CN 102994500 B CN102994500 B CN 102994500B
Authority
CN
China
Prior art keywords
nucleotides
sirna
eye
modified
ocular
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201210278029.7A
Other languages
English (en)
Chinese (zh)
Other versions
CN102994500A (zh
Inventor
E·法因施泰因
E·艾伯特
I·梅特
A·巴-伊兰
I·斯皮瓦克
H·卡林斯基
N·斯拉格尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Suzhou Ruibo Biotechnology Co ltd
Original Assignee
Quark Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Quark Pharmaceuticals Inc filed Critical Quark Pharmaceuticals Inc
Publication of CN102994500A publication Critical patent/CN102994500A/zh
Application granted granted Critical
Publication of CN102994500B publication Critical patent/CN102994500B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201210278029.7A 2008-10-22 2009-10-22 治疗眼部疾病的方法 Active CN102994500B (zh)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US19699508P 2008-10-22 2008-10-22
US61/196,995 2008-10-22
US19893108P 2008-11-11 2008-11-11
US61/198,931 2008-11-11
IL2009000179 2009-02-15
ILPCT/IL2009/000179 2009-02-15

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN2009801517703A Division CN102449151A (zh) 2008-10-22 2009-10-22 治疗眼部疾病的方法

Publications (2)

Publication Number Publication Date
CN102994500A CN102994500A (zh) 2013-03-27
CN102994500B true CN102994500B (zh) 2015-04-01

Family

ID=54839547

Family Applications (3)

Application Number Title Priority Date Filing Date
CN201210278029.7A Active CN102994500B (zh) 2008-10-22 2009-10-22 治疗眼部疾病的方法
CN201510090523.4A Active CN104857526B (zh) 2008-10-22 2009-10-22 治疗眼部疾病的方法
CN2009801517703A Pending CN102449151A (zh) 2008-10-22 2009-10-22 治疗眼部疾病的方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN201510090523.4A Active CN104857526B (zh) 2008-10-22 2009-10-22 治疗眼部疾病的方法
CN2009801517703A Pending CN102449151A (zh) 2008-10-22 2009-10-22 治疗眼部疾病的方法

Country Status (17)

Country Link
US (4) US8765931B2 (https=)
EP (1) EP2350279B1 (https=)
JP (1) JP5592892B2 (https=)
KR (1) KR101672563B1 (https=)
CN (3) CN102994500B (https=)
AU (1) AU2009308380B2 (https=)
BR (1) BRPI0919683A2 (https=)
CA (2) CA2962219C (https=)
DK (1) DK2350279T3 (https=)
EA (1) EA022418B1 (https=)
ES (1) ES2563984T3 (https=)
HU (1) HUE026751T2 (https=)
IL (1) IL212986A (https=)
NZ (1) NZ591391A (https=)
PL (1) PL2350279T3 (https=)
SI (1) SI2350279T1 (https=)
WO (1) WO2010048352A2 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104857526A (zh) * 2008-10-22 2015-08-26 夸克制药公司 治疗眼部疾病的方法

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009147684A2 (en) * 2008-06-06 2009-12-10 Quark Pharmaceuticals, Inc. Compositions and methods for treatment of ear disorders
CN102282155B (zh) 2008-12-02 2017-06-09 日本波涛生命科学公司 磷原子修饰的核酸的合成方法
RU2612521C2 (ru) 2009-07-06 2017-03-09 Онтории, Инк. Новые пролекарства нуклеиновых кислот и способы их применения
CN104313027B (zh) * 2009-08-11 2018-11-20 库尔纳公司 通过抑制脂连蛋白(adipoq)的天然反义转录物治疗脂连蛋白(adipoq)相关疾病
AU2010324658A1 (en) 2009-11-26 2012-05-03 Quark Pharmaceuticals, Inc. siRNA compounds comprising terminal substitutions
WO2012006083A2 (en) * 2010-07-09 2012-01-12 University Of Florida Research Foundation, Inc. Targeted receptor-mediated sirna
JP5868324B2 (ja) 2010-09-24 2016-02-24 株式会社Wave Life Sciences Japan 不斉補助基
CN103796657B (zh) 2011-07-19 2017-07-11 波涛生命科学有限公司 合成官能化核酸的方法
AU2012332517B9 (en) 2011-11-03 2017-08-10 Quark Pharmaceuticals, Inc. Methods and compositions for neuroprotection
US20140323549A1 (en) * 2011-11-08 2014-10-30 Quark Pharmaceuticals, Inc. Methods and compositions for treating diseases, disorders or injury of the nervous system
EP2800812A1 (en) 2012-01-04 2014-11-12 Quark Pharmaceuticals, Inc. Double-stranded rna compounds to casp2 and uses thereof
PL2872485T3 (pl) 2012-07-13 2021-05-31 Wave Life Sciences Ltd. Asymetryczna grupa pomocnicza
KR102213609B1 (ko) 2012-07-13 2021-02-08 웨이브 라이프 사이언시스 리미티드 키랄 제어
CA2879066C (en) 2012-07-13 2019-08-13 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant
ES2704855T3 (es) 2012-09-12 2019-03-20 Quark Pharmaceuticals Inc Moléculas de oligonucleótido de doble cadena para p53 y métodos de uso de las mismas
EP2895607B1 (en) 2012-09-12 2021-05-05 Quark Pharmaceuticals, Inc. Double-stranded oligonucleotide molecules to ddit4 and methods of use thereof
CN104661682B (zh) * 2012-09-27 2018-05-11 千寿制药株式会社 水性液剂
EP2970972B1 (en) * 2013-03-11 2018-08-15 Fondazione Telethon Mir-204 and mir-211 and uses thereof
IL288931B2 (en) 2013-03-14 2025-05-01 Alnylam Pharmaceuticals Inc Compositions comprising a complementary portion of C5 IRNA and methods of using them
JPWO2015108047A1 (ja) 2014-01-15 2017-03-23 株式会社新日本科学 免疫誘導活性を有するキラル核酸アジュバンド及び免疫誘導活性剤
JPWO2015108048A1 (ja) 2014-01-15 2017-03-23 株式会社新日本科学 抗腫瘍作用を有するキラル核酸アジュバンド及び抗腫瘍剤
US10322173B2 (en) 2014-01-15 2019-06-18 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having anti-allergic activity, and anti-allergic agent
BR112016016400A2 (pt) 2014-01-16 2017-10-03 Wave Life Sciences Ltd Composições de oligonucleotídeos quiralmente controlados, seu uso, sua composição farmacêutica, e métodos
WO2016040589A1 (en) 2014-09-12 2016-03-17 Alnylam Pharmaceuticals, Inc. Polynucleotide agents targeting complement component c5 and methods of use thereof
US20160319278A1 (en) 2015-04-03 2016-11-03 University Of Massachusetts Fully stabilized asymmetric sirna
WO2017030973A1 (en) 2015-08-14 2017-02-23 University Of Massachusetts Bioactive conjugates for oligonucleotide delivery
US10752896B2 (en) 2015-09-08 2020-08-25 Sylentis Sau siRNA and their use in methods and compositions for inhibiting the expression of the NRARP gene
EP3487507A4 (en) * 2016-07-21 2020-04-08 American Gene Technologies International, Inc. VIRAL VECTORS FOR THE TREATMENT OF PARKINSON'S DISEASE
EP3512948A4 (en) * 2016-09-09 2020-05-13 Cornell University ADMINISTRATION OF NUCLEIC ACIDS, PROTEINS AND SMALL MOLECULES IN GLASS-LIKE VESICULAR BODIES
US20180092776A1 (en) 2016-09-30 2018-04-05 Sara Heikali Method and device for treating and managing diseased ocular tissue
RU2766353C2 (ru) * 2016-11-02 2022-03-15 Фридрих Мишер Инститьют Фор Байомедикал Рисерч Synp198, промотор для специфической экспрессии генов в ганглионарных клетках сетчатки, избирательных в отношении направления
RU2633349C1 (ru) * 2016-11-24 2017-10-11 Федеральное государственное автономное учреждение "Межотраслевой научно-технический комплекс "Микрохирургия глаза" имени академика С.Н. Федорова" Министерства здравоохранения Российской Федерации Способ определения дифференцированных показаний к срокам лечения нарушений прекорнеальной слезной пленки после лазерного in situ кератомилеза с фемтолазерным сопровождением у детей
CA3043768A1 (en) 2016-11-29 2018-06-07 PureTech Health LLC Exosomes for delivery of therapeutic agents
RU2643579C1 (ru) * 2017-03-29 2018-02-02 Федеральное государственное автономное образовательное учреждение высшего образования "Белгородский государственный национальный исследовательский университет" (НИУ "БелГУ") Способ профилактики ишемической нейропатии зрительного нерва карбамилированным дарбэпоэтином в эксперименте
JP7406793B2 (ja) 2017-06-23 2023-12-28 ユニバーシティー オブ マサチューセッツ ２テイル自己デリバリー型ｓｉＲＮＡおよび関連方法
SG11202002940QA (en) 2017-11-01 2020-04-29 Alnylam Pharmaceuticals Inc Complement component c3 irna compositions and methods of use thereof
CN110604811B (zh) * 2018-06-14 2023-01-31 陕西慧康生物科技有限责任公司 含有重组人溶菌酶和重组人表皮生长因子的人工泪液
CN113528510A (zh) 2018-06-29 2021-10-22 武汉纽福斯生物科技有限公司 治疗遗传性视神经病变的组合物和方法
SG11202101032VA (en) * 2018-08-20 2021-02-25 Wuhan Neurophth Biotechnology Ltd Company Compositions and methods for treating leber's hereditary optic neuropathy
US11279930B2 (en) 2018-08-23 2022-03-22 University Of Massachusetts O-methyl rich fully stabilized oligonucleotides
AU2019343188A1 (en) 2018-09-21 2021-05-20 Aufbau Medical Innovations Limited Compositions and methods for glaucoma
CN113614232A (zh) 2019-01-18 2021-11-05 马萨诸塞大学 动态药代动力学修饰锚
EP3914205A4 (en) * 2019-01-22 2022-09-14 The Board of Trustees of the Leland Stanford Junior University SILICONE OIL INDUCED HYPERPRESSURE AND GLAUCOMA MODEL
KR20220047989A (ko) 2019-08-09 2022-04-19 유니버시티 오브 매사추세츠 Snp를 표적화하는 화학적으로 변형된 올리고뉴클레오타이드
US12365894B2 (en) 2019-09-16 2025-07-22 University Of Massachusetts Branched lipid conjugates of siRNA for specific tissue delivery
WO2021081026A1 (en) 2019-10-22 2021-04-29 Alnylam Pharmaceuticals, Inc. Complement component c3 irna compositions and methods of use thereof
JP2021080253A (ja) * 2019-11-19 2021-05-27 ジョンソン・アンド・ジョンソン・コンシューマー・インコーポレイテッドＪｏｈｎｓｏｎ ＆ Ｊｏｈｎｓｏｎ Ｃｏｎｓｕｍｅｒ Ｉｎｃ． 眼を治療するための組成物及び方法
US11969451B2 (en) 2019-11-19 2024-04-30 Johnson & Johnson Surgical Vision, Inc. Compositions and methods for treating the eye
CN113025633B (zh) 2019-12-09 2024-08-27 武汉纽福斯生物科技有限公司 编码人nadh脱氢酶亚单位1蛋白的核酸及其应用
TWI819268B (zh) * 2020-01-16 2023-10-21 詹姆斯 Ｗ 希爾 藉由基因轉導改變眼睛顏色
WO2021242883A1 (en) 2020-05-26 2021-12-02 University Of Massachusetts Synthetic oligonucleotides having regions of block and cluster modifications
CN112063624A (zh) * 2020-09-19 2020-12-11 湖南中医药大学 一种抑制caspase 1基因表达的siRNA分子及其应用
WO2022223515A2 (en) 2021-04-19 2022-10-27 Novo Nordisk A/S Compositions and methods for inhibiting nuclear receptor subfamily 1 group h member 3 (nr1h3) expression
WO2023014654A2 (en) * 2021-08-02 2023-02-09 University Of Massachusetts Oligonucleotides for htt-1a modulation
CN118302525A (zh) 2021-10-29 2024-07-05 阿尔尼拉姆医药品有限公司 补体因子B（CFB）iRNA组合物及其使用方法
CN116548384B (zh) * 2023-04-12 2026-02-13 电子科技大学 一种青光眼干预疾病模型的构建方法
EP4560019A1 (en) 2023-11-22 2025-05-28 Sylentis S.A.U. Sirna and compositions for prophylactic and therapeutic treatment of ocular retinal conditions
EP4560020A1 (en) 2023-11-22 2025-05-28 Sylentis S.A.U. Sirna and compositions for prophylactic and therapeutic treatment of ocular retinal conditions

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002024720A1 (en) * 2000-09-20 2002-03-28 Isis Pharmaceuticals, Inc. Antisense modulation of caspase 2 expression
US6602858B2 (en) * 1997-03-31 2003-08-05 Ribozyme Pharmaceuticals, Inc. Nucleic acid catalysts comprising L-nucleotide analogs
WO2008050329A2 (en) * 2006-10-25 2008-05-02 Quark Pharmaceuticals, Inc. Novel sirnas and methods of use thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060217331A1 (en) * 2001-05-18 2006-09-28 Sirna Therapeutics, Inc. Chemically modified double stranded nucleic acid molecules that mediate RNA interference
US20050282188A1 (en) * 2001-05-18 2005-12-22 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using short interfering nucleic acid (siNA)
US20030157030A1 (en) * 2001-11-02 2003-08-21 Insert Therapeutics, Inc. Methods and compositions for therapeutic use of rna interference
DE60310944T3 (de) * 2002-08-05 2017-08-03 Silence Therapeutics Gmbh Weitere neue formen von interferierende rns moleküle
AU2004217437B2 (en) * 2003-03-05 2009-11-19 Senesco Technologies, Inc. Use of antisense oligonucleotides or siRNA to suppress expression of eIF-5A1
FR2855054B1 (fr) * 2003-05-22 2005-07-08 Theraptosis Moyens pour bloquer ou retarder une mort cellulaire in vitro
EP1626732B1 (en) * 2003-05-22 2013-04-03 CHIESI FARMACEUTICI S.p.A. Means for preventing and treating cellular death and their biological applications
EP2319925B1 (en) * 2004-08-16 2018-07-25 Quark Pharmaceuticals, Inc. Therapeutic uses of inhibitors of RTP801
TW200639252A (en) * 2005-02-01 2006-11-16 Alcon Inc RNAi-mediated inhibition of ocular hypertension targets
US20100292301A1 (en) 2007-02-28 2010-11-18 Elena Feinstein Novel sirna structures
RU2487716C2 (ru) 2007-10-03 2013-07-20 Кварк Фармасьютикалс, Инк. Новые структуры малых интерферирующих рнк (sirna)
CA2962219C (en) * 2008-10-22 2020-08-25 Quark Pharmaceuticals, Inc. Methods for treating eye disorders

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6602858B2 (en) * 1997-03-31 2003-08-05 Ribozyme Pharmaceuticals, Inc. Nucleic acid catalysts comprising L-nucleotide analogs
WO2002024720A1 (en) * 2000-09-20 2002-03-28 Isis Pharmaceuticals, Inc. Antisense modulation of caspase 2 expression
WO2008050329A2 (en) * 2006-10-25 2008-05-02 Quark Pharmaceuticals, Inc. Novel sirnas and methods of use thereof

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104857526A (zh) * 2008-10-22 2015-08-26 夸克制药公司 治疗眼部疾病的方法

Also Published As

Publication number Publication date
KR20110081826A (ko) 2011-07-14
US20150050328A1 (en) 2015-02-19
ES2563984T3 (es) 2016-03-17
PL2350279T3 (pl) 2016-05-31
IL212986A0 (en) 2011-07-31
NZ591391A (en) 2012-10-26
JP5592892B2 (ja) 2014-09-17
CN102449151A (zh) 2012-05-09
DK2350279T3 (en) 2016-02-15
CN104857526B (zh) 2019-03-05
US9701961B2 (en) 2017-07-11
CA2962219A1 (en) 2010-04-29
AU2009308380B2 (en) 2015-05-28
WO2010048352A3 (en) 2010-06-17
IL212986A (en) 2016-05-31
US8765931B2 (en) 2014-07-01
HUE026751T2 (en) 2016-07-28
US9121020B2 (en) 2015-09-01
EP2350279A2 (en) 2011-08-03
KR101672563B1 (ko) 2016-11-03
SI2350279T1 (sl) 2016-04-29
WO2010048352A2 (en) 2010-04-29
EP2350279B1 (en) 2016-01-27
CA2738957A1 (en) 2010-04-29
BRPI0919683A2 (pt) 2020-12-08
AU2009308380A1 (en) 2010-04-29
WO2010048352A8 (en) 2011-08-11
US20150361430A1 (en) 2015-12-17
CN104857526A (zh) 2015-08-26
EA201170551A1 (ru) 2011-12-30
HK1183693A1 (zh) 2014-01-03
US20170306329A1 (en) 2017-10-26
JP2012506450A (ja) 2012-03-15
US20110229557A1 (en) 2011-09-22
CN102994500A (zh) 2013-03-27
HK1212883A1 (zh) 2016-06-24
CA2962219C (en) 2020-08-25
EA022418B1 (ru) 2015-12-30

Similar Documents

Publication Publication Date Title
CN102994500B (zh) 治疗眼部疾病的方法
WO2008104978A2 (en) Novel sirna structures
WO2011072091A1 (en) Methods and compositions for treating diseases, disorders or injury of the cns
JP7394815B2 (ja) ＮＲＡＲＰ遺伝子の発現を阻害するためのｓｉＲＮＡ、並びにそのための方法及び組成物におけるそれらの使用
CN103097534B (zh) 针对rhoa的双链rna化合物及其用途
EP2776565A1 (en) Methods and compositions for treating diseases, disorders or injury of the nervous system
HK1212883B (zh) 治疗眼部疾病的方法
HK1183693B (en) Methods for treating eye disorders
HK1152235A (en) Novel sirna compounds for inhibiting rtp801

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1183693

Country of ref document: HK

CB02 Change of applicant information
CB02 Change of applicant information

Address after: American California

Applicant after: Quark Pharmaceuticals, Inc.

Address before: American California

Applicant before: Quark Pharmaceuticals, Inc.

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1183693

Country of ref document: HK

TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20230705

Address after: No. 168 yuan Feng Road, Yushan Town, Kunshan City, Suzhou, Jiangsu

Patentee after: Suzhou Ruibo Biotechnology Co.,Ltd.

Address before: California, USA

Patentee before: Quark Pharmaceuticals, Inc.